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Digoxinhas beena controversialdrugsinceits introduction
>200yearsago.Althoughitsefficacyinpatientswithheartfailure









that digoxinmayalso haveclinicalvaluein mildheartfailure,





of digitalisin patientswith heart failure,this drug has been
subjectto debateandcontroversy(2-5).Althoughthevalueof
digoxininpatientswithheartfailurewhohaveatrialfibrillation
has generallybeen recognized,its efficacyin thosewho have
sinus rhythmhas often been questioned.Nevertheless,the
drughascontinuedto be widelyusedin the UnitedStates(2)
and Europe, possiblybecause “old habits die slowly”(5).
Renewedscientificinterest emerged,however,when it was
foundthat digitalishad a significanteffecton neurohumoral
activationand autonomicfunction in patients with heart
failure (6), an effectthat may explainsomeof its (alleged)
favorablepropertiesin thissyndrome(7).
Duringthe lastdecade,the popularityof digoxinhasagain
increased.Thishasbeenpartlydueto the resultsofthreelarge
scale trialspublishedat the end of the 1980sthat did not
primarilyinvestigatedigoxinitselfbut used it as a reference
drug (8-10). In these three placebo-controlledtrials,which
studied>300 patientstakingdigoxin,the drugwasfoundto











tion.Mo, thereis evidencethat relativelylowdoses of digoxin
maybe at least as effectiveas higherdoses and havea lower
incidenceof sideeffects.Further,the recognitionthatthe use of
digoxintooearlyaftermyocardialinfarctionmaybeharmfuland





althonghdigoxinhas a neutraleffecton total mortalityduring
long-termtreatmen~it reducesthe numberof hospitaladmis-
sionsanddeathsdueto worseningheartfailure.Thepotentially
newfeaturesof theolddrugdigoxinarediscussedin this review.
(JAnrCOUCardiol1996;28:813-9)
causea statisticallysignificantimprovementin exercisetime
(10) and left ventricularejectionfraction(8,10)and to de-
creasesignsand symptomsof heart failure(9). In the begin-
ningof the 1990s,twootherplacebo-controlledstudies(11,12)
showeda beneficialeffectof digoxinon exercisecapacity,
ejectionfractionand clinicalvariables,both in the presence
(11) and in the absence (12) of concomitantangiotensin-
convertingenzymetherapy. However,both studies had a
withdrawaldesign,and the questionremainswhether their
resultscanbe appliedto patientsinwhomdigoxirrtreatmentis
initiated(3,13).
In recent years, evidencehas accumulatedthat disease
progressionin chronicheart failure is related not only to
hemodynamicbut also to neurohumoralfactors (14). As a
consequence,it hasbecomeclearthat a pronouncedbeneficial
hemodynamiceffectof a drug is not necessarilyrelated to a
decrease in morbidityand mortality.The autonomicand
neurohumoraleffectsof a drug mayin this respectbe more
predictive(15),an observationthat has also led to renewed
interest in digoxin.Other new developments,such as the
successfuluseof lowerdosesof digoxin,havealsocontributed
to thisrevivedinterest.In thisreview,wediscussrecentdataon
digoxinand place these data againstthe backgroundof the














namicdisorderand, as a result,drugtreatmenthas primarily
attempted to correct hemodynamicabnormalities(14,17).
However,the conceptof the pathophysiologyof heart failure
haschangedduringthe last 10years,and recentdata strongly
supportan importantrole for neurohumoralmodulationor




In the past, digitalishas been considereda pure positive
inotropicagent.As a result,the disappointingresultsof some
largescaletrialswithpositiveinotropicagentsinthe 1980s(20)
led to concern that similardisappointingeffectscould be
expectedwithdigoxin(21),particularlybecausethedeleterious
effectsof inotropicdrugsappear to be independentof their
mechanismof action (22). In recent years, evidencehas
emerged that digoxinexerts its inotropiceffectsmainlyat
higherdoses;at lowerdoseslittle inotropicactionbut more
pronouncedneurohumoraleffectsare observed(23).
Severalstudiesnowavailablehaveevaluatedthe neurohu-
moral and autonomiceffectsof digoxin.Digitalisappeamto
modulatesympathetictone(7)in a mannersimilarto thatof its
hemodynamiceffects,whichditlerbetweenhealthyvolunteers
and patientswithheart failure(24).In heart failure,it will,in
general,have a sympathoinhibitoryeffect,dependingon the
severityof the disease(25)andon the doseused(23,26).There
are severalpotentialexplanationsfor theneuroendoerineinhib-
itoryeffectsof digitalisin heart failure(6,7),but the observed
improvementor normalizationof impaired baroreceptor-
mediatedmechanismsappearsto playan importantrole(26,27),
althoughnotallstudies(28)supporthisconcept.A reductionof
sympathetictone in heart failurehas been demonstratedby
directlymeasuringefferentsympatheticnerveactivityin skeletal
muscle(6)or,moreeasily,bydeterminingplasmanorepinephrine
concentrations.In two olderstudies(29,30)it wasshownthat
digoxinimmediatelyreducedplasmanorepinephrineconcentra-















In addition to these neurohormonalactions, effectsof
digitalison both cardiopulmonaryand arterialbaroreceptor
functionin humanshavelongbeen recognized(7,26,37-41).
Becausebaroreceptorsmodulatesympatheticand parasympa-
thetic(orvagal)activityas a resultof stretchof the mechano-
receptors,neurohormonalchangesmeasuredin plasmaand
muscle,as describedearlier,are directlyrelatedto the effects




suggested,including1) a directreceptoreffect,2) an increase




heartfailure,and changesin heartrate variabilityindexesmay
havesomepredictivevaluewithregardto the long-termefficacy
of drugsin this syndrome(15).Recently,three studieshave
examinedtheeffectsof digoxinon heartratevariabilityindexes,
bothinpatientswithheartfailure(43,44)andinnormalsubjects
(45).Krum et al. (43) studiedpatientswith moderateheart
failure,mostofwhomreceivedbackgroundtreatmentwithcon-
vertingenzymeinhibitors.After4 to 8 weeksof treatmentwith




study,Brouweret al. (44)examined patientswith mildheart
failurewho had been receivingeitherlowdosediureticdrugs
aloneor no medicationfor heartfailure.After3 months,heart
ratevariabilityindexesdeterioratedslightlyin theplacebogroup
but improvedsignifhntlyin the digoxingroupcomparedwith
valuesin thepatientsreceivingplacebo.Theseobservations(44)




modulation.In linewiththe observedeffectson sympathovagal
balance,digoxinmaypartlyrestoretheimpairedcircadianpattern
ofheartratevariability(44)thatisobservedinpatientswithheart
failure(46).Thiseffectappearsto be relatedto changesin the
circadianpattern of circulatingplasmanorepinephrineafter
digoxinadministration.Thistindingobviouslyraisesnewques-
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Figure1. Effects of digoxinon time domain and frequency domain
heart rate variability indexes. Changes are expressed as percent of
baselinevalue.Patients with heart failure not treated with angiotensin-
converting enzyme inhibitors who generally had mild heart failure
(mean left ventricular ejection fraction 0.28[hatchedbars];data from
Brouweret al. [44])are comparedwith patients whowere treated with
these drugs and had more advancedor moderate heart failure (mean
ejection fraction 0.22[cross-hatchedbars];data from Krumet al. [43])
*p< 0.05;*p< 0.005.HF = high frequencypower (0.15to 0.40Hz)
(ins’); LF = low frequencypower (0.04to 0.15Hz) (ins’); pNN50 =










thisassumptionwasconfirmedin a meta-analysisof digoxinin
1990(57).However,in a subsequentreview,Gheorghiadeand
Figure 2. Effectsof6monthsofmonotherapy
withdigoxin(n = 22,solidbars)or placebo
(n = 20,openbars) on exercisetime,plasma
norepinephrineand plasmareninin patients
withmildheart failure.*p <0.05. Adapted
fromvanVeldhuisenet al. (31).
Exercise Time
Zarowitz(58)pointedout that evidenceexistedthat the drug




(n= 55),ibopamine(n = 53)or placebo(n = 53).Theresr.dts
showedthatdigoxinsignificantlyimprovedexercisetimeoverthat
achievedwithplaceboafter6 months.Subanalysisof the data
indicatedthat the drugwasindeedrelativelymoreeffectivein
patientswithmoreadvanceddisease(25).Nevertheless,digoxin
was alsoeffectivein patientswithmilddisease,and when its
effectsasmonotherapywereanalyzed(inthe 64patients[40%]
whodidnotreceivediureticdrugsatbaseline),digoxinwasfound
to be more effectivethan placebobecauseit significantlyim-
provedexercisetimeandreducedplasmaneurohormonesafter6




Just et al. (59)studied222patientswhowere randomizedto






22),ibopamine(n = 18)or placebo(n = 20),andthesepatients
werefollowedup foronly4weeks.Duringthatstudytherewere
no treatmentfailuresin thegroupreceivingdigoxin,andquality
oflifeimprovedin 21of the22patients.In general,digoxinwas
comparableto ibopamineand significantlymoreeffectivethan
placebo.
Digoxin Dosage: Higher Is Not
Necessarily Better
Another importantissuein the use of digitalishas been
establishmentof the optimaldose (23,61).In the past,when












lowerdosesof digoxinmayalsobe effectiveand resultin less
toxicity(23).In anearlypostinfarctiontrial(62),serumdigoxin
concentrationswereassociatedwithan adverseprognosis,but
this associationwas no longer statisticallysignificantafter
adjustmentfor otherriskfactors.However,in a subanalysisof
a largeheart failuretrial (ProspectiveRandomizedMilrinone
SurvivalEvaluation[PROMISE]study) (63), high serum
digoxinlevels(>1.1 rig/ml)were found to be independently
relatedto an adverseprognosis.Somerecent“positive”find-
ings(25,43,44),suchas favorableeffectsof digoxinon plasma
neurohormonesand heart rate variability,were observedin
patientswhowerereceivinglowdosesof the drug.In a recent
study(64),whenthe dailydoseof digoxinwasincreasedfrom
0.2030.1 mg/dayto 0.39t 0.1mg/day(whichcorresponded
to serum levelsof 0.7 t 0.2 rig/mland 1.2 f 0.4 rig/ml,
respectively),left ventricularejectionfractionincreased,but
neurohormonesdid not decrease. Indeed, increasingthe
digoxindoseto theseserumlevelsmayimproveleftventricular
(systolic)function(64,65),but lowerdosesmay alreadybe
effectivein the suppressionofneurohormones,an observation




ular failure and the Efficacyof Digoxin(PROVED) and
RandomizedAssessmentof Digoxinon Inhibitorsof the
AngiotensinConvertingEnzyme(RADIANCE)trials(66)and
fromothers(67)suggesthat tryingto pushthe digoxindoseto
serumlevelsabovekl.2 rig/mlmaybe questionable,whereas
increasingthe dose to levels 1.5 to 2.0 rig/mlis probably
unwanted(51). However,it is difficultto compare serum
digoxinconcentrationsamong studiesbecause there is no
standardizedtimeafterdosingfor obtainingserumlevels,and
severalothertechnicalproblemsmaycauseadditionalbias(67).
If lower doses of digoxinare used, the number of side
effects,includingseriousadverseevents,suchas arrhythmias,





Digoxin Should Be Given With Caution After
Myocardial Infarction
Several large retrospective studies have examined theeffect
of digitalis in acute myocardial infarction (62,73,74).Although
thesestudiesgenerallyshowthatpatientstreatedwithdigitalis
faredworsethanthosewhowerenot,theirfindingsare limited
by the fact that mostpatientswhowere takingdigitaliswere
doingso becausetheysufferedfrommore severelyimpaired
leftventricularfunction(75).Nevertheless,a recentlargescale
study(76)that correctedfor all confoundingfactors(suchas




two olderstudies,digoxinwasfoundnot to affeetpreloador
atlerload(77)orto improvehemodynamics(78).Inanotherstudy
(79),digoxinimprovedhemodynamicsbut onlyin patientswith












use of digoxinshouldin generalbe avoidedin the (sub)acute
phaseafter infarction,unIessthere is strongindicationfor its
administrationsuchas rapidatrialfibrillation.In the past,heart
failurein the acutephaseof myocardialinfarctionwas often
treatedwithdigoxin(82,83),but this is no longerthe general
practice.One factormay be that digoxinmay aggravatethe
clinicalconditionin the settingof cardiogenicshock(88)and,
therefore,dobutamineor dopamineisnowoftenusedinstead.In
addition,the positiveresultsof recent large scaletrialswith
angiotensin-convertingenzymeinhibitorsin thissetting(89,90)
havealsoplayeda rolein thischange,
Other Possible Factors in the Declining Role
of Digoxin in Heart Failure
Otherfactorsmayalsohavebeen involvedin the declining
roleof digoxinin heartfadurein the late 1970sandearly1980s.
At that time,angiotensin-convertingenzymeinhibitorsbeeame






drugs,and manyphysiciansare now eveninclinedto initiate






Anotherimportant,often neglectedfactoris the fact that
digoxinisa veryinexpensivedrug.As a result,pharmaceutical
companieshavenotbeenenthusiasticto startmajortrialswith
thisdrug.Thus,the largescaledigoxinsurvivaltrial,the DIG









were sponsoredby the companiesmanufacturingthesecom-
pounds(8,10,25,59).The lowcostof digoxinobviouslyhas a
positiveside,anda recenthealthcareanalysis(97)showedthat
discontinuationof digoxinin patientswithstableheart failure
leadsto increasedeconomiccosts.
Effects of Digoxin on Mortality
With Heart Failure
in Patients
Until recently,only retrospectiveand uncontrolleddata
wereavailableconcerningthe effectof digoxinon mortalityin
patientswithchronicheart failure.For thisreason,the large
scaleDIG trialwas designedand sponsoredby the National
Institutesof Health in conjunctionwith the Departmentof
VeteransAffairsCooperativeStudiesProgram(16,96,98).In
this double-blind,parallelgroup comparison,patientswith
heart failureand sinusrhythmwere randomizedto receive
digoxinor placeboin additionto other medication.Patients
were requiredto havecurrentor past evidenceof signsand
symptomsof heart failure and a left ventricularejection
fractionsO.45.In a parallel,separatesmallerstudy(f1,000
patients)the effectsin thosewith an ejectionfraction>0.45
werestudied.Theprimaryendpointofthestudywastheeffect
of digitalison totalmortality;secondaryendpointsincludeda
(first)hospitaladmissionfor worseningheart failureor other
causes,cardiovascularmortality,deathdueto worseningheart
failureand (presumed)arrhythmias,and effectson qualityof





Preliminaryanalysisof the results(16)showedthat digoxin
hadnoeffecton totalmortalityduringa meanfollow-uperiod
of >3 years.However,the numberof hospitaladmissionsand
the number of deaths due to worseningheart failurewere
significantlyreduced by digoxin,whereas the incidenceof
presumedarrhythmiadeaths and deaths due to myocardial
infarctiontended to increase.Althoughthere wassomesug-
gestionthat the reductionin risk of worseningheart failure
achievedby digoxinwasmostpronouncedin patientswith a









or serumlevelson clinicaloutcome.Resultsof qualityof life
assessmentwerenotyet available.
Summary
The use of digoxinin patientswithheart failureand sinus
rhythmhas been controversialfor >200 years.Manyof the
positivedata on digoxinhave been gainedfrom withdrawal
trialsand have thereforeoften been criticized.Severalpro-
spective,double-blindrandomizedstudiespublishedin the last
fewyearshaveshednewlightonthevalueandplaceofdigoxin
in the treatment of patients with heart failure and sinus
rhythm.Furthermore,preliminaryresultsof DIG, the large
scalemortalitytrial,haveyieldedimportantnewinformation
aboutthis drug.The mainfindingfromthat studyto date is
that digoxinhas a neutraleffecton totalmortalityin patients
withheartfailure.However,the drughassignificantlyreduced
the number of deaths due to worseningheart failure and
relatedhospitaladmissions,data that suggesthat it mayslow
progressionof the disease.Althoughthe finaldata havenot
been published,the resultsdo not clearlypoint in one direc-
tion, and it is thereforelikelythat the controversyregarding
thisdrugwillcontinue.Fromthesenewerdataandfromother
developmentswithregardto the insightsinto the pathophysi-
ologyandtreatmentof heartfailure,severalissuesconcerning
the valueand useof digoxinhavebecomeclear.
1) In lightof the generallyacceptedimportanceof neuro-
humoralactivationin the pathophysiologyof heartfailure,the
recentlyrecognizedpositiveneurohumoraleffectsof digoxin
(includingits influenceon baroreceptorfunctionand heart
rate variability)seempromising.2) Althoughdigoxinappears
to be most effectivein advancedheart failure,severalnew
studiesshowthatitmayalsobe ofvalueinpatientswithmilder
stagesof the disease.In the latter,however,it isbydefinition
moredifficulto showa significantdrugeffect,and studiesin
thispatientgroupshouldthusbeconductedwithlargersample
sizesand a longerfollow-upperiod,as has been done with
angiotensin-convertingenzymeinhibitors(99). 3) Relatively
highdosesof digoxinhavetraditionallybeenused,but recent
data suggestthat lowerdosesmaybe effectiveas well.When
lowerdosesare used, fewerside effectswilloccur,and the
subjectivewell-beingof the patientmayimprove.4) Patients
with a new or fairlyrecent myocardialinfarctionshould,in
general,probablynot be treated with digoxin,and the drug
shouldbe usedwithsomecautionin patientswhohaveheart
failureafterinfarction.Becausedigoxinhasoftenbeenadmin-
isteredto these patientsin the past, the negativeresultsof
somereported trialsmaybe partlyexplainedby this factor.
Finally,otherfactorsmaybe involvedin the decliningroleof
digoxin in heart failure, includingthe increased use of
angiotensin-convertingenzymeinhibitors,and the low cost
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